Print Friendly, PDF & Email

NCT/Study#

NCT04277637 /

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation And Expansion Study Of Bcl-2 Inhibitor BGB-11417 In Patients With Mature B-Cell Malignancies

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: